Published in J Immunol on November 15, 2008
CD28(-) T cells: their role in the age-associated decline of immune function. Trends Immunol (2009) 2.66
Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol (2009) 2.09
Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. EMBO Mol Med (2012) 1.66
Vaccination in the elderly: an immunological perspective. Trends Immunol (2009) 1.60
Early immune senescence in HIV disease. Curr HIV/AIDS Rep (2010) 1.58
The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. Aging Cell (2011) 1.55
Role of CD8 T Cell Replicative Senescence in Human Aging and in HIV-mediated Immunosenescence. Aging Dis (2011) 1.33
T cell replicative senescence in human aging. Curr Pharm Des (2013) 1.31
A natural product telomerase activator as part of a health maintenance program. Rejuvenation Res (2010) 1.30
Telomere/telomerase dynamics within the human immune system: effect of chronic infection and stress. Exp Gerontol (2010) 1.23
Telomeres and immunological diseases of aging. Gerontology (2009) 1.22
Aging and immune function: molecular mechanisms to interventions. Antioxid Redox Signal (2011) 1.18
Assessing cell and organ senescence biomarkers. Circ Res (2012) 1.17
Telomerase at the intersection of cancer and aging. Trends Genet (2013) 1.16
Sustained CD28 expression delays multiple features of replicative senescence in human CD8 T lymphocytes. J Clin Immunol (2010) 1.10
Tumor suppressor mechanisms in immune aging. Curr Opin Immunol (2009) 1.08
Modulation of T lymphocyte replicative senescence via TNF-{alpha} inhibition: role of caspase-3. J Immunol (2009) 1.07
Kleemeier Award Lecture 2008--the canary in the coal mine: telomeres and human healthspan. J Gerontol A Biol Sci Med Sci (2009) 1.00
Translational research in immune senescence: assessing the relevance of current models. Semin Immunol (2012) 1.00
IFN-γ upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells. PLoS One (2010) 0.96
Telomeres and immune competency. Curr Opin Immunol (2012) 0.94
Potential of telomerase activation in extending health span and longevity. Curr Opin Cell Biol (2012) 0.92
HIV-1 Vpr protein inhibits telomerase activity via the EDD-DDB1-VPRBP E3 ligase complex. J Biol Chem (2013) 0.91
Predicting cytotoxic T-cell age from multivariate analysis of static and dynamic biomarkers. Mol Cell Proteomics (2010) 0.88
Genetic Variations in Telomere Maintenance, with Implications on Tissue Renewal Capacity and Chronic Disease Pathologies. Curr Pharmacogenomics Person Med (2010) 0.87
A novel telomerase activator suppresses lung damage in a murine model of idiopathic pulmonary fibrosis. PLoS One (2013) 0.85
Telomerase reverse transcriptase-dependent telomere equilibration mitigates tissue dysfunction in mTert heterozygotes. Dis Model Mech (2009) 0.84
Increased telomerase activity and vitamin D supplementation in overweight African Americans. Int J Obes (Lond) (2011) 0.84
Impact of aging on viral infections. Microbes Infect (2010) 0.84
Pharmaceutical regulation of telomerase and its clinical potential. J Cell Mol Med (2012) 0.83
A challenge for the future: aging and HIV infection. Immunol Res (2010) 0.83
The silent war of CMV in aging and HIV infection. Mech Ageing Dev (2015) 0.79
Disruptive chemicals, senescence and immortality. Carcinogenesis (2015) 0.78
Epigenetic regulation of telomerase expression in HIV-1-specific CD8+ T cells. AIDS (2010) 0.77
Therapeutic Targeting of Telomerase. Genes (Basel) (2016) 0.76
Human immune compartment comparisons: Optimization of proliferative assays for blood and gut T lymphocytes. J Immunol Methods (2017) 0.75
Oxidative stress and age-related changes in T cells: is thalassemia a model of accelerated immune system aging? Cent Eur J Immunol (2016) 0.75
Functional assessment of pharmacological telomerase activators in human T cells. Cells (2013) 0.75
A Natural Product Telomerase Activator Lengthens Telomeres in Humans: A Randomized, Double Blind, and Placebo Controlled Study. Rejuvenation Res (2016) 0.75
Evaluation of an oral telomerase activator for early age-related macular degeneration - a pilot study. Clin Ophthalmol (2016) 0.75
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
Telomere measurement by quantitative PCR. Nucleic Acids Res (2002) 18.69
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science (1995) 17.42
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol (1994) 15.93
Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med (1999) 14.30
Telomerase catalytic subunit homologs from fission yeast and human. Science (1997) 12.35
Association between telomere length in blood and mortality in people aged 60 years or older. Lancet (2003) 10.56
Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A (1992) 10.19
Telomerases. Annu Rev Biochem (1992) 3.83
Telomere length is paternally inherited and is associated with parental lifespan. Proc Natl Acad Sci U S A (2007) 3.67
Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study. Aging Cell (2006) 3.44
Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol (1995) 3.20
Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. J Immunol (1996) 3.03
Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends Biochem Sci (1998) 2.75
Homeostasis of the naive CD4+ T cell compartment during aging. J Immunol (2008) 2.48
Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem (1999) 2.34
Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging. Immunol Rev (1997) 2.13
Divergent telomerase and CD28 expression patterns in human CD4 and CD8 T cells following repeated encounters with the same antigenic stimulus. Clin Immunol (2002) 1.97
Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine (2007) 1.78
Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential. Blood (2001) 1.71
Telomeres, telomerase and senescence. Bioessays (1990) 1.70
Mechanism of telomerase induction during T cell activation. Exp Cell Res (1996) 1.68
Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene (2005) 1.64
Telomerase levels control the lifespan of human T lymphocytes. Blood (2003) 1.59
Genetic manipulation of telomerase in HIV-specific CD8+ T cells: enhanced antiviral functions accompany the increased proliferative potential and telomere length stabilization. J Immunol (2004) 1.58
Human immunodeficiency virus type 1 modulates telomerase activity in peripheral blood lymphocytes. J Infect Dis (2000) 1.57
Telomere length in leukocytes correlates with bone mineral density and is shorter in women with osteoporosis. Osteoporos Int (2007) 1.55
Human cytomegalovirus infection and T cell immunosenescence: a mini review. Mech Ageing Dev (2006) 1.53
CD8+ cells in human immunodeficiency virus type I pathogenesis: cytolytic and noncytolytic inhibition of viral replication. Adv Immunol (1997) 1.52
Immortalization of human CD8+ T cell clones by ectopic expression of telomerase reverse transcriptase. J Immunol (2000) 1.45
CD8 T cells and aging. Crit Rev Immunol (2003) 1.44
Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status. Proc Natl Acad Sci U S A (1999) 1.37
Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol (2004) 1.31
Transcriptional regulation of telomerase activity: roles of the the Ets transcription factor family. Ann N Y Acad Sci (2007) 1.21
Rapid telomere erosion in schizophrenia. Mol Psychiatry (2008) 1.20
Telomerase activity of HIV-1-specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors. Blood (2008) 1.20
Enzyme-linked immunosorbent assay spot detection of interferon-gamma and interleukin 5-producing cells as a predictive marker for renal allograft failure. Transplantation (1998) 1.10
Differential impairment of lytic and cytokine functions in senescent human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. J Virol (2003) 1.09
Association between telomere length and heart disease in a narrow age cohort of older people. Exp Gerontol (2006) 1.05
Autologous CD4/CD8 co-culture assay: a physiologically-relevant composite measure of CD8+ T lymphocyte function in HIV-infected persons. J Immunol Methods (2007) 1.04
Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. Oncogene (2002) 1.04
T-cell dysregulation caused by chronic antigenic stress: the role of CMV in immunosenescence? Aging Clin Exp Res (2006) 0.94
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell (2008) 4.02
Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol (2007) 3.59
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA (2002) 2.96
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
Measurement of telomere length by the Southern blot analysis of terminal restriction fragment lengths. Nat Protoc (2010) 2.88
HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci (2007) 2.75
Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr (2002) 2.70
Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis (2012) 2.64
Homeostasis of the naive CD4+ T cell compartment during aging. J Immunol (2008) 2.48
Hydrodynamic stretching of single cells for large population mechanical phenotyping. Proc Natl Acad Sci U S A (2012) 2.37
Optimization of methods to assess human mucosal T-cell responses to HIV infection. J Immunol Methods (2003) 2.32
Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation. Blood (2003) 2.29
Cross-clade detection of HIV-1-specific cytotoxic T lymphocytes does not reflect cross-clade antiviral activity. J Infect Dis (2008) 2.18
Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci U S A (2002) 2.14
Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol (2009) 2.09
Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS (2003) 2.05
Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. J Infect Dis (2008) 2.01
Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model. Am J Epidemiol (2007) 2.00
Divergent telomerase and CD28 expression patterns in human CD4 and CD8 T cells following repeated encounters with the same antigenic stimulus. Clin Immunol (2002) 1.97
Nef interference with HIV-1-specific CTL antiviral activity is epitope specific. Blood (2006) 1.91
Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood (2012) 1.85
A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther (2002) 1.83
Reduced telomerase activity in human T lymphocytes exposed to cortisol. Brain Behav Immun (2008) 1.82
Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS (2003) 1.81
Premature aging of T cells is associated with faster HIV-1 disease progression. J Acquir Immune Defic Syndr (2009) 1.78
Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains. J Virol (2005) 1.77
Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med (2011) 1.73
Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men. J Acquir Immune Defic Syndr (2009) 1.69
Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene (2005) 1.64
Vaccination in the elderly: an immunological perspective. Trends Immunol (2009) 1.60
Genetic manipulation of telomerase in HIV-specific CD8+ T cells: enhanced antiviral functions accompany the increased proliferative potential and telomere length stabilization. J Immunol (2004) 1.58
The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. Aging Cell (2011) 1.55
Beyond help: direct effector functions of human immunodeficiency virus type 1-specific CD4(+) T cells. J Virol (2004) 1.51
Epitope-dependent avidity thresholds for cytotoxic T-lymphocyte clearance of virus-infected cells. J Virol (2007) 1.48
Copy number variation of KIR genes influences HIV-1 control. PLoS Biol (2011) 1.44
Challenges for vaccination in the elderly. Immun Ageing (2007) 1.42
Estimating the benefit of an HIV-1 vaccine that reduces viral load set point. J Infect Dis (2007) 1.41
Parallel human immunodeficiency virus type 1-specific CD8+ T-lymphocyte responses in blood and mucosa during chronic infection. J Virol (2005) 1.41
The theta-defensin, retrocyclin, inhibits HIV-1 entry. AIDS Res Hum Retroviruses (2003) 1.40
Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency. J Clin Invest (2017) 1.39
Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther (2004) 1.37
Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis (2010) 1.37
Epitope escape mutation and decay of human immunodeficiency virus type 1-specific CTL responses. J Immunol (2003) 1.36
A frailty-related phenotype before HAART initiation as an independent risk factor for AIDS or death after HAART among HIV-infected men. J Gerontol A Biol Sci Med Sci (2011) 1.36
Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. J Acquir Immune Defic Syndr (2013) 1.34
Role of CD8 T Cell Replicative Senescence in Human Aging and in HIV-mediated Immunosenescence. Aging Dis (2011) 1.33
Cocaine enhances human immunodeficiency virus replication in a model of severe combined immunodeficient mice implanted with human peripheral blood leukocytes. J Infect Dis (2002) 1.33
Assessing immunophenotyping performance: proficiency-validation for adopting improved flow cytometry methods. Cytometry B Clin Cytom (2007) 1.32
Comparison of interlaboratory variation in absolute T-cell counts by single-platform and optimized dual-platform methods. Cytometry B Clin Cytom (2010) 1.31
T cell replicative senescence in human aging. Curr Pharm Des (2013) 1.31
Regulatory T cell expansion and immune activation during untreated HIV type 1 infection are associated with disease progression. AIDS Res Hum Retroviruses (2009) 1.28
Effect of TERT over-expression on the long-term transplantation capacity of hematopoietic stem cells. Nat Med (2003) 1.28
Meeting the challenge of hematologic malignancies in sub-Saharan Africa. Blood (2012) 1.26
Biomimetic enzyme nanocomplexes and their use as antidotes and preventive measures for alcohol intoxication. Nat Nanotechnol (2013) 1.23
The dual impact of HIV-1 infection and aging on naïve CD4 T-cells: additive and distinct patterns of impairment. PLoS One (2011) 1.23
Genetic and stochastic influences on the interaction of human immunodeficiency virus type 1 and cytotoxic T lymphocytes in identical twins. J Virol (2005) 1.22
A biochemical fluorometric method for assessing the oxidative properties of HDL. J Lipid Res (2011) 1.17
HIV-1 adapts to a retrocyclin with cationic amino acid substitutions that reduce fusion efficiency of gp41. J Immunol (2006) 1.17
Impacts of epitope expression kinetics and class I downregulation on the antiviral activity of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. J Virol (2004) 1.17
A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res (2003) 1.15
In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells. PLoS Pathog (2012) 1.14
Telomere length assessment in tissue sections by quantitative FISH: image analysis algorithms. Cytometry A (2004) 1.14
Sustained CD28 expression delays multiple features of replicative senescence in human CD8 T lymphocytes. J Clin Immunol (2010) 1.10
Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp Neurol (2012) 1.10
Oxidized lipids enhance RANKL production by T lymphocytes: implications for lipid-induced bone loss. Clin Immunol (2009) 1.09
Differential impairment of lytic and cytokine functions in senescent human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. J Virol (2003) 1.09
Degeneracy and repertoire of the human HIV-1 Gag p17(77-85) CTL response. J Immunol (2006) 1.08
Imetelstat (GRN163L)--telomerase-based cancer therapy. Recent Results Cancer Res (2010) 1.07
Modulation of T lymphocyte replicative senescence via TNF-{alpha} inhibition: role of caspase-3. J Immunol (2009) 1.07
How many human immunodeficiency virus type 1-infected target cells can a cytotoxic T-lymphocyte kill? J Virol (2005) 1.07
Half-genome human immunodeficiency virus type 1 constructs for rapid production of reporter viruses. J Virol Methods (2003) 1.06
Autologous CD4/CD8 co-culture assay: a physiologically-relevant composite measure of CD8+ T lymphocyte function in HIV-infected persons. J Immunol Methods (2007) 1.04
Functional adaptation of Nef to the immune milieu of HIV-1 infection in vivo. J Immunol (2008) 1.04
Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology (2005) 1.04
Bronchoalveolar immunologic profile of acute human lung transplant allograft rejection. Transplantation (2008) 1.04
Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition. Clin Cancer Res (2011) 1.02
Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia. AIDS Res Hum Retroviruses (2010) 1.02
Accelerated aging in HIV/AIDS: novel biomarkers of senescent human CD8+ T cells. PLoS One (2013) 1.01
Simultaneous flow cytometric analysis of two cell surface markers, telomere length, and DNA content. Cytometry (2002) 1.01
Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments. Vaccine (2008) 1.01